Q-Line Biotech Ltd

AI

Q-Line Biotech Ltd

₹ 408 -0.83%
19 Nov - close price
About

Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]

Key Points

Business Profile:[1]
Q-Line Biotech is an Indian in-vitro
diagnostics (IVD) company engaged
in developing, manufacturing, marketing
and distributing diagnostic reagents, consumables, point-of-care (POC)
devices and diagnostic equipment.
The company primarily serves
diagnostic laboratories, hospitals
and medical colleges through
a B2B distribution-led model.

  • Market Cap ₹ 952 Cr.
  • Current Price ₹ 408
  • High / Low ₹ 735 / 396
  • Stock P/E 17.4
  • Book Value ₹ 206
  • Dividend Yield 0.00 %
  • ROCE 22.4 %
  • ROE 26.0 %
  • Face Value ₹ 10.0

Pros

  • Company has reduced debt.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 92.7 to 134 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Sep 2025 Mar 2026 Sep 2026
217 144 198 152
172 108 136 113
Operating Profit 45 36 62 40
OPM % 21% 25% 31% 26%
-11 3 2 4
Interest 8 8 11 10
Depreciation 3 4 7 8
Profit before tax 22 26 46 26
Tax % 71% 19% 26% 24%
9 21 34 20
EPS in Rs 5.18 12.49 20.15 8.40
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
183 203 313 342 350
149 165 242 244 248
Operating Profit 34 38 71 98 102
OPM % 18% 19% 23% 29% 29%
2 3 -14 5 6
Interest 4 6 15 19 21
Depreciation 2 4 7 11 15
Profit before tax 30 31 35 73 72
Tax % 28% 29% 55% 23%
32 34 19 56 54
EPS in Rs 18.80 20.17 11.25 32.63 28.55
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 23%
TTM: -3%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 21%
TTM: 54%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 24%
Last Year: 26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 2 2 2 16 23
Reserves 126 160 188 230 458
74 97 166 225 132
51 81 99 87 76
Total Liabilities 252 339 455 559 690
23 60 91 158 145
CWIP 12 19 63 19 16
Investments 16 29 0 0 18
201 232 302 381 511
Total Assets 252 339 455 559 690

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
25 -24 17 16
-26 -45 -77 -29
26 17 53 42
Net Cash Flow 25 -52 -7 29
Free Cash Flow -5 -72 -53 -19
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 111% -39% 36% 43%

Ratios

Consolidated / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 66 47 96 134
Inventory Days 180 413 225 258
Days Payable 164 232 139 142
Cash Conversion Cycle 82 228 183 251
Working Capital Days -44 51 45 62
ROCE % 16% 24% 22%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Sep 2026
Capacity Utilization - Clinical Chemistry/Rapid/Elisa Kits (Unit 3)
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Geographic Revenue Mix - North India
% ・Standalone data
Instrument Revenue Share
% ・Standalone data
Number of Customers Served
count ・Standalone data
Number of Distributors
count ・Standalone data
Reagent Revenue Share
% ・Standalone data
Capacity Utilization - Selectra Pro M Analyzers (Unit 2)
% ・Standalone data
Manufacturing Capacity - Selectra Pro M Analyzers (Unit 2)
units per year ・Standalone data
Installed Base - Selectra Pro M Analyzers
count ・Standalone data
Product Licences Granted
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

May 2026Sep 2026
67.51% 67.51%
1.67% 0.88%
10.14% 8.15%
20.67% 23.45%
No. of Shareholders 3,4972,948

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents